Clinical Scorecard: Comparative Analysis of Therapeutic Donor Lymphocyte Infusion versus Second Allogeneic Transplantation Following Relapse in Acute Leukemia and Myelodysplastic Syndromes
At a Glance
Category
Detail
Condition
Key Mechanisms
Therapeutic donor lymphocyte infusion (DLI) enhances graft-versus-leukemia (GvL) effect, particularly in hematologic relapse; second allo-HCT is an alternative intervention.
Target Population
Care Setting
Key Highlights
highlight_3
Guideline-Based Recommendations
Diagnosis
Management
Therapeutic DLI administered in the setting of hematologic relapse or clinical progression, considering patient-specific factors.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
DLI is more commonly used in patients with advanced relapse or limited treatment tolerance; consider patient age, comorbidities, and previous treatment responses.
Clinical Best Practices
Individualize treatment based on patient performance status and clinical circumstances, including specific examples of multidisciplinary discussions for treatment decisions.
